ReachMD
Be part of the knowledge.™Innovations in Oncology: Gastrointestinal Cancers
How could emerging data on novel immuno-oncology (IO) strategies change your approach to therapy?
This educational series examines the current role of immunotherapy in gastric cancers and explores the future direction of IO therapy in treatment. Our globally renowned experts provide an update on advances to care that you can apply to your practice today. They also review National Comprehensive Cancer Network guidelines pertaining to patients with MSI-H/dMMR or HER2+ colorectal cancer; gastric, esophageal, and gastroesophageal junction cancers; and advanced hepatocellular carcinoma.
Provided by:
In Partnership with:
Episodes 1-3 of 3
Optimizing Care for Patients with Advanced Hepatocellular Carcinoma: Current Standards and Future Directions with Immunotherapy
CME/CEOptimizing Care for Patients with Advanced Hepatocellular Carcinoma: Current Standards and Future Directions with Immunotherapy
Immune-Based Advances in Gastric, Esophageal, and Gastroesophageal Junction Cancers
CME/CEImmune-Based Advances in Gastric, Esophageal, and Gastroesophageal Junction Cancers
Advances in the Care of Patients with MSI-H/dMMR or HER2+ Colorectal Cancers
CME/CEAdvances in the Care of Patients with MSI-H/dMMR or HER2+ Colorectal Cancers
